Revenue
2016
2017
2018
2019
2020
2021
2022
2023
NYMOX PHARMACEUTICAL CORP (NYMXF)
Price—Loading quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2016
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $5,000 | $116,000 | $299,000 | $224,000 | $284,000 | $2.8M |
| Research & development | $3.3M | $4.0M | $3.8M | $6.7M | $8.1M | $7.4M | $6.7M | $7.9M | $6.8M | $8.7M |
| Operating income | −$4.3M | −$8.3M | −$6.7M | −$12.5M | −$11.7M | −$13.3M | −$10.6M | −$13.2M | −$12.9M | −$17.7M |
| Net income | −$4.5M | −$8.8M | −$6.6M | −$12.5M | −$11.7M | −$13.2M | −$10.6M | −$13.4M | −$13.1M | −$17.9M |
| Basic EPSper diluted share | -$0.05 | -$0.10 | -$0.07 | -$0.15 | -$0.16 | -$0.19 | -$0.18 | -$0.26 | -$0.28 | -$0.48 |
| Diluted EPSper diluted share | — | — | — | — | -$0.16 | -$0.19 | -$0.18 | -$0.26 | -$0.28 | -$0.48 |